The European Commission has approved its seventh Advanced Purchase Agreement (APA) with a pharmaceutical company to ensure access to a potential vaccine against COVID-19 in Q4 of 2021 and in 2022. Under this contract, Member States will be able to purchase up to 100 million doses of the Novavax vaccine, with an option for 100…
On Friday, a second contract with a pharmaceutical company entered into force following the contact’s formal signature between Sanofi-GSK and the Commission. The contract will allow all EU Member States to purchase up to 300 million doses of the Sanofi-GSK vaccine. Moreover, Member States may donate reserved doses to lower- and middle-income countries. Sanofi and GSK…
The European Commission says it has concluded exploratory talks with CureVac to purchase a potential vaccine against COVID-19. This is following the positive steps with Sanofi-GSK on 31 July and Johnson and Johnson on 13 August and the signature of an Advance Purchase Agreement with AstraZeneca on 14 August. The envisaged contract with CureVac would…
